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E-mail: m.azzouz@shefﬁeld.ac.ukOf familial amyotrophic lateral sclerosis (fALS) cases, 20% are
caused by mutations in the gene encoding human cytosolic
Cu/Zn superoxide dismutase (hSOD1). Efﬁcient translation of
the therapeutic potential of RNAi for the treatment of SOD1-
ALS patients requires the development of vectors that are free
of signiﬁcant off-target effects and with reliable biomarkers
to discern sufﬁcient target engagement and correct dosing.
Using adeno-associated virus serotype 9 to deliver RNAi against
hSOD1 in the SOD1G93A mouse model, we found that intra-
thecal injection of the therapeutic vector via the cisterna magna
delayed onset of disease, decreased motor neuron death at end
stage by up to 88%, and prolonged the median survival of
SOD1G93Amice by up to 42%. To our knowledge, this is the ﬁrst
report to demonstrate no signiﬁcant off-target effects linked to
hSOD1 silencing, providing further conﬁdence in the speciﬁcity
of this approach. We also report the measurement of cerebro-
spinal ﬂuid (CSF) hSOD1 protein levels as a biomarker of effec-
tive dosing and efﬁcacy of hSOD1 knockdown. Together, these
data provide further conﬁdence in the safety of the clinical ther-
apeutic vector. The CSF biomarker will be a useful measure of
biological activity for translation into human clinical trials.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating progressive and
fatal neurodegenerative disorder. Most commonly presenting as a
late-onset adult disorder, ALS typically results in death from respira-
tory failure approximately 3–5 years from disease onset. ALS is pri-
marily characterized by the degeneration of upper and lower motor
neurons, and, as a result, patients experience widespread and debili-
tating muscle atrophy and weakness. In addition to impaired move-
ment, muscle atrophy leads to further problems, including difﬁculty
swallowing, talking, and breathing. Of ALS cases, 90% are sporadic
(sALS), with the remaining 10% having an identiﬁable hereditary
component (familial ALS [fALS]).
The ﬁrst dominant gain-of-function mutations found to cause fALS
were discovered in 1993 in the gene encoding the antioxidant proteinMolecular Therap
This is an open access article under the CC BY-NCsuperoxide dismutase 1 (SOD1).1 Since then, many pathogenic muta-
tions have been discovered throughout the SOD1 gene, and the
genetic etiology of sporadic and fALS has expanded dramatically to
implicate more than 30 different genes.2,3 More than two decades
of research has demonstrated that the process of motor neuron injury
in the presence of SOD1 mutations is complex, involving multiple
pathophysiological processes.4 This complexity produces difﬁculties
for neuroprotective therapy development. Therefore, the upstream
strategy of lowering the expression of the mutant SOD1 protein using
gene therapy is compelling, particularly as knockout mouse models
show that this can be done relatively safely.5
Other than palliative care, the available treatments for ALS only
marginally inﬂuence survival (riluzole) or disability progression
(edaravone).6,7 Gene therapy shows great promise for the treatment
of SOD1-linked fALS. Speciﬁcally, lentiviral delivery of a short
hairpin RNA (shRNA) targeting human SOD1 (hSOD1) mRNA
can delay disease progression and extend survival in mice carrying
the SOD1 G93A mutation.8,9 This approach was further conﬁrmed
by Foust et al.,10 who exchanged the lentiviral vector for a self-com-
plementary recombinant adeno-associated virus serotype 9 (scAAV9)
vector10 more suitable for use in human clinical trials.11
In the present proof-of-concept study, we evaluated the therapeutic
efﬁcacy of scAAV9-shRNA-mediated SOD1 silencing deliveredy: Nucleic Acids Vol. 12 September 2018 ª 2018 The Author(s). 75
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Cisterna Magna Delivery of scAAV9_hSOD1si in SOD1G93A Mice Efficiently Reduces hSOD1 mRNA and Protein in Brain, Spinal Cord, and CSF
(A–F) qRT-PCR analysis shows depletion of hSOD1 mRNA in brainstem (A), cerebellum (B), striatum (C), cortex (D), and lumbar spinal cord (E) 4 weeks post-cisterna magna
delivery of scAAV9_hSOD1si in post-natal day 1 (P1) SOD1G93A mice. ELISA analysis shows a significant decrease in hSOD1 protein in CSF from the same group of mice (F).
Data are presented as box and whiskers plot showing median, 25th and 75th percentiles, and maximum and minimum values. Data were analyzed by Student’s one-tailed
t test (unpaired) (A–E, nR 6; F, nR 4). *p < 0.05, **p < 0.01, and ***p < 0.001.
Molecular Therapy: Nucleic Acidsintrathecally via the cisterna magna in the SOD1G93A mouse model at
post-natal day 1 (P1) or 40 (P40) using a vector conﬁguration ready
to be translated into a human clinical trial for SOD1-linked fALS.
The ﬁndings reported here are timely and are of great relevance for
clinical translation as follows: (1) evaluation of the ﬁnal clinical conﬁg-
uration of the therapeutic vector led to remarkable efﬁcacy in the
SOD1G93A mouse model; (2) to our knowledge, this is the ﬁrst report
to demonstrate no signiﬁcant off-target effects linked to scAAV9-
mediated SOD1 silencing, providing further conﬁdence in the speci-
ﬁcity and safety of the clinical therapeutic vector we have developed;
and (3) we report the measurement of cerebrospinal ﬂuid (CSF)
hSOD1 protein level as a biomarker of effective dosing and efﬁcacy of
SOD1 knockdown. The same approach will be used as a readout for
the biological activity of our therapeutic vector when administered in
fALS patients.
RESULTS
Validation of the Clinical Therapeutic Vector for scAAV9-
Mediated hSOD1 Silencing
Clinical conﬁguration of the therapeutic vector was designed by the
group of Brian Kaspar at Nationwide Childrens Hospital, Columbus,
OH, USA. The scAAV backbone contains an H1 promoter to drive
expression of the shRNA targeted against the hSOD1 gene. We ﬁrst
ensured that the therapeutic vector was functional and able tomediate
hSOD1 depletion. Given that our previous studies revealed that
cisterna magna is an attractive route of delivery for gene transfer to
the CNS,12 we set out to assess the efﬁciency of scAAV9_hSOD1si
for SOD1 depletion in SOD1G93A mice, a widely used mouse model
of ALS. P1 mice (n = 9) received scAAV9_hSOD1si (5  1010 vector76 Molecular Therapy: Nucleic Acids Vol. 12 September 2018genomes [vg]/g) via the cisterna magna. A second group of animals
(n = 10) was treated with scrambled control vector scAAV9_
hSOD1ssi (5 1010 vg/g). CNS tissue and CSF samples were collected
from these mice 4 weeks post-vector delivery and used to measure
hSOD1 mRNA and protein levels. scAAV9_hSOD1si-injected
animals displayed lower levels of hSOD1 compared with controls in
all the analyzed CNS regions. Speciﬁcally, we found a reduction in
hSOD1mRNAof 38% (Figure 1A), 43% (Figure 1B), 56% (Figure 1C),
45% (Figure 1D), and 26% (Figure 1E) in brainstem, cerebellum,
striatum, cortex, and lumbar spinal cord, respectively.
One of the major bottlenecks in therapy development for neurode-
generation and for ALS in particular is the lack of reliable biomarkers
for easy assessment of the therapeutic readouts. We therefore set
out to evaluate the impact of our gene-based therapeutics at lowering
the hSOD1 protein levels in the CSF of treated mice. Interestingly,
analysis of CSF revealed the depletion in hSOD1 protein by 63%
in scAAV_hSOD1si-treated animals when compared to controls
(Figure 1F; p = 0.0142). Together, these data suggest that the thera-
peutic vector is functional and that CSF SOD1 protein levels can be
used as a reliable biomarker to discern sufﬁcient target engagement
and correct dosing in future clinical trials in SOD1-associated ALS
patients.
Single scAAV9_hSOD1si Administration at Disease Pre-onset
(P1) ImprovesMotor Performance and Neurological Deficits and
Extends Survival in SOD1G93A Mice
Widespread delivery of therapeutic genes to the CNS is a formi-
dable challenge in ALS therapy for many reasons. First, delivery of
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Figure 2. Cisterna Magna Delivery of scAAV9_hSOD1si at Post-natal Day 1 Improves Motor Performance and Survival in SOD1G93A Mice
(A–F) Graphs showing body weight (A), rotarod performance measured as time to fall in seconds against age in days (B), area under the curve (AUC) of rotarod performance
(C), neuroscoring (D), survival analysis (E), and onset of symptoms (F) in SOD1G93A mice injected with 2.5e+10 vg/g scAAV9_hSOD1si (n = 9) or scAAV9_SOD1ssi
(n = 10) via the cisterna magna at P1. Student’s t test of AUC data showed improved rotarod performance (C) in scAAV9_hSOD1si-treated mice, when compared with
scAAV9_hSOD1ssi. In all graphs data are presented as the mean ± SEM. **p < 0.01, ***p < 0.001, and ****p < 0.0001.
www.moleculartherapy.orgtherapeutic genes into motor neurons is restricted by the blood-
brain barrier (BBB). Second, due to the severe nature of SOD1-
associated ALS, SOD1 silencing would be desirable at early stages
of the disease. We therefore intentionally chose the cisterna magna
as the route of delivery, as we and others have reported that CSF
delivery of scAAV9 produced very efﬁcient, robust, and widespread
gene transfer to the CNS in mice.12–14 To evaluate the efﬁcacy of
hSOD1 silencing on the motor phenotype in the SOD1G93A mouse
model, scAAV9_hSOD1si (n = 9) or scAAV9_hSODssi (n = 10)
vectors were administered intrathecally via the cisterna magna of
mice at P1.
Daily inspection of the phenotype of the animals revealed that
scAAV9_hSOD1si-injected mice displayed continuous body weight
gain (Figure 2A), while scAAV9_hSOD1ssi-treated animals showed
signs of reduced weight gain starting from P50 (Figure 2A).
To objectively quantify motor performance of treated SOD1G93A
mice, we used the rotarod (Figures 2B and 2C) and neuroscoring
(Figure 2D). Rotarod tasks detected ﬁrst motor deﬁcits around
50–60 days of age in scAAV9_hSOD1ssi control mice, which
became rapidly more severe and very pronounced by 70 days of
age (Figure 2B). In contrast, the scAAV9_hSOD1si-treated animals
still performed normally at 110–120 days of age. Some therapeuti-
cally treated mice started to display motor performance deﬁcits ataround 140 days (Figure 2B). Neuroscoring analysis was performed
to assess the splay defects in the two groups of mice. Control-
injected mice displayed an increase in hind limb splay defects
when compared with scAAV9_hSOD1si-treated mice (Figure 2D;
p < 0.0001). Taken together, pre-onset delivery of scAAV9-mediated
SOD1 silencing led to a remarkable motor improvement in the
SOD1G93A mouse model of ALS. Notably, scAAV9_hSOD1si-treated
mice lacked obvious paralysis and continued to remain ambulant
even at end stage.
The mean onset of clinical disease (deﬁned by 20% drop in motor
performance as assessed by rotarod task) was delayed by 67 days
in scAAV9_hSOD1si-treated mice (n = 9) as compared to control
animals (n = 10) (123 ± 16.1 versus 56.7 ± 2.2; p < 0.001) (Fig-
ure 2F). Interestingly, lifespan analysis in scAAV9_hSOD1si-treated
SOD1G93A mice revealed a median prolongation of the life expectancy
by as much as 42% compared to control animals (207 ± 12.4 days
versus 145.5 ± 3.1 days; p < 0.0001) (Figure 2E).
SOD1 Depletion Improves Motor Neuron Survival and Reduces
Gliosis in SOD1G93A Mice
Since early anatomical changes in the SOD1G93A models of ALS are
seen in lower motor neurons,15 we quantiﬁed calcitonin gene-related
peptide (CGRP)-positive lumbar motor neurons at end stage.16 Cell
counts revealed that the number of CGRP-labeled motor neuronsMolecular Therapy: Nucleic Acids Vol. 12 September 2018 77
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Figure 3. Cisterna Magna Delivery of scAAV9_hSOD1si in SOD1G93A Mice at Post-natal Day 1 Efficiently Improves Lumbar Motor Neuron Survival at End
Stage and Reduces Gliosis
(A and B) Representative images of motor neurons in lumbar spinal cord ventral horn from mice treated at P1 with scAAV9_hSOD1si (A, main 20, inset 63; scale bar,
100 mm) or scAAV9_hSOD1ssi (B, main 20, inset 63; scale bar, 100 mm), stained for CGRP (green), and quantified in (C) (n = 20 sections/mouse, 5 mice per group).
(C–H) Representative images of Nissl-stained lumbar spinal cord from mouse treated at P1 with scAAV9_hSOD1si (D, scale bar, 100 mm; E, scale bar, 250 mm) or scAAV9_
hSOD1ssi (F, scale bar, 100 mm; G, scale bar, 250 mm) and quantified in (H) (n = 10 sections/mouse, 3 mice per treatment group). (I–L) Representative images of lumbar cord
ventral horn frommouse treated at P1 with scAAV9_hSOD1si (I,scale bar, 50 mm; J, scale bar, 100 mm) or scAAV9_hSOD1ssi (K, scale bar, 50 mm; L, scale bar, 100 mm) and
stained for GFAP (magenta), Iba1 (yellow), and DAPI (cyan). *p < 0.05.
Molecular Therapy: Nucleic Acidsin lumbar spinal cord sections was signiﬁcantly higher in scAAV9_
hSOD1si-treated mice (n = 5; p = 0.047) (Figure 3A) compared to
scAAV9_hSOD1ssi (n = 5) (Figure 3B), which was consistent with
an improvement in motor neuron survival of 87.8% (Figure 3C).
Motor neurons were also quantiﬁed by Nissl staining in lumbar spinal
cord sections (Figure 3H), and they showed a signiﬁcantly higher
number of motor neurons per section in scAAV9_hSOD1si-treated
mice (n = 3; p = 0.028) (Figures 3D and 3E) compared to scAAV9_
hSOD1ssi (n = 3) (Figures 3F and 3G).
Previous histopathological characterization of the spinal cords of
SOD1G93A mice revealed increased expression of glial ﬁbrillary acidic
protein (GFAP) and ionized calcium-binding adaptor molecule 1
(Iba1), markers of astrocytes and microglia, respectively, indicative
of elevated reactive gliosis and inﬂammation.17 Spinal cord sections
from end-stage mice treated with scAAV9_hSOD1si showed a reduc-
tion in both GFAP and Iba1 staining (Figures 3I and 3J) compared to
control mice (Figures 3K and 3L).78 Molecular Therapy: Nucleic Acids Vol. 12 September 2018Single scAAV9_hSOD1si Administration at Disease Onset (P40)
Improves Motor Performance and Neurological Deficits,
and It Extends Survival in SOD1G93A Mice
As treatment of ALS patients is currently initiated only after disease
diagnosis, testing the therapeutic potential of SOD1 silencing at the
onset of clinical symptoms in SOD1G93A mice is mandatory. Cisterna
magna delivery of scAAV9_hSOD1si (8 109 vg/g) was subsequently
applied in SOD1G93A mice at P40. Gene transfer to the CSF through
the cisterna magna can be easily translated to human clinical trials
using intrathecal delivery via lumbar puncture. Using the intrathecal
route of delivery provides advantages for translational applications,
since a smaller quantity of the vector is required compared to systemic
administration of AAV and allows for a reduced number of viral
particles reaching peripheral organs, such as the liver.18,19
Consistent with the P1 data, assessment of neuromuscular function
using the rotarod task showed a signiﬁcant improvement up to
133 days of age in scAAV9_hSOD1si-treated mice when compared
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C D
30 40 50 60 70 80 90 100 110 120
14
16
18
20
22
Age (days)
60 80 100 120
0.0
0.5
1.0
1.5
 
0 50
0
50
100
120 160 185
E F
G
B
Vector delivery
B
od
y 
w
ei
gh
t (
g)
N
eu
ro
sc
or
in
g
P
er
ce
nt
 s
ur
vi
va
l
La
te
nc
y 
to
 fa
ll 
(s
ec
)
H I
Tubulin
hSOD1
Brainstem Cerebellum
1 2 3 4
18kDa
50kDa
55 110
0
50
100
150
200
250
300
165
Time (days)
40

183
0
5000
10000
15000
20000
25000

Day 126
0
50
100
150 
scAAV9_hSOD1si
scAAV9_hSOD1ssi
scAAV9_hSOD1si
scAAV9_hSOD1ssi
scAAV9_hSOD1si
scAAV9_hSOD1ssi
scAAV9_hSOD1si
scAAV9_hSOD1si scAAV9_hSOD1ssi
scAAV9_hSOD1si scAAV9_hSOD1ssi
Age (days)
La
te
nc
y 
to
 fa
ll 
(s
)
La
te
nc
y 
to
 fa
ll 
(A
U
C
)
Age (days)
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
scAAV9_hSOD1ssi
scAAV9_hSOD1si
scAAV9_hSOD1ssi
scAAV9_hSOD1si
 
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e


Brainstem Cerebellum
Mean survival,
scAAV9_hSOD1si vs 
scAAV9_hSOD1ssi
unpaired t-test
p value = <0.0001
Figure 4. Cisterna Magna Delivery of scAAV9_hSOD1si at Post-natal Day 40 Improves Motor Performance and Extends Life Expectancy in SOD1G93A Mice
(A–F) Graphs showing rotarod performance measured as time to fall in seconds against age in days (A) and area under the curve (AUC) of rotarod performance (B), histogram
showing the effect of scAAV9_hSOD1si on rotarod performance at day 126 (C), neuroscoring (D), body weight (E), and survival analysis (F). (G–I) Representative western blot
(G) of SOD1 knockdown in brainstem and cerebellum of P40-treated mice, where 1 and 3 are scAAV9_hSOD1si treated and 2 and 4 are scAAV9_hSOD1ssi treated, and
quantification of hSOD1 protein expression in brainstem (H) and cerebellum (I) at end stage in SOD1G93A mice injected with clinical vector scAAV9_hSOD1si at P40. Western
(legend continued on next page)
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Figure 5. Cisterna Magna Delivery of
scAAV9_hSOD1si at P40 Improves Gait Parameters
in SOD1G93A Mice
(A–D) Analysis of individual gait parameters over time
in SOD1G93A transgenic mice injected with scAAV9_
hSOD1si (n = 5) or scAAV9_hSOD1ssi (n = 5) in the
cisterna magna at post-natal day 40 (P40). Selected gait
parameters were analyzed using a two-way ANOVA
with Sidak’s post hoc test. Forepaw stride length in mil-
limeters (A), forepaw pixel intensity (B), hind paw stride
length in millimeters (C), and hind paw swing speed in
meters per second (D) for SOD1G93A mice treated with
scAAV9_hSOD1si or scAAV9_hSOD1ssi are shown.
Data are presented as mean ± SEM. Differences were
detectable at day 91. *p < 0.05 and **p < 0.01.
Molecular Therapy: Nucleic Acidswith scAAV9_hSOD1ssi (p < 0.001) (Figure 4A). The area under
the curve (AUC) for rotarod data showed overall improved motor
performance (Figure 4B) in scAAV9_hSOD1si-treated mice when
compared with scAAV9_hSOD1ssi (n = 15; p < 0.0001), and
scAAV_hSOD1si-treated mice had a signiﬁcantly longer latency to
fall (measured in seconds) at 126 days old compared to scramble-
treated controls (Figure 4C). Neuroscoring analysis revealed
improvement in hind limb splay defects following SOD1 depletion
when compared with control mice (Figure 4D; n = 15; p < 0.0001).
Body weight was signiﬁcantly decreased in scAAV9_hSOD1ssi-
treated mice at day 120 compared to scAAV9_hSOD1si-treated
mice (n = 15; p < 0.01), as assessed by two-way ANOVA with Sidak’s
post hoc test (Figure 4E). scAAV9_hSOD1ssi-treated SOD1G93A mice
survived to a median age of 138 ± 1.9 days of age (n = 15) (Fig-
ure 4F). In contrast, SOD1G93A mice treated with scAAV9_hSOD1si
showed a statistically signiﬁcant extension in lifespan to a median of
157 ± 2.9 days of age (n = 15; p < 0.0001) (Figure 4F).
We used western blotting to determine hSOD1 protein levels in brain-
stem and cerebellum from scAAV9_hSOD1si and -ssi virus-treatedblot data were analyzed by Student’s one-tailed t test (nR 9 per group), *p < 0.05 and ***p < 0.001. Student’s
(B and C) and neuroscoring (D) in scAAV9_hSOD1si-treated mice compared with scAAV9_hSOD1ssi (n = 15 pe
(F) in scAAV9-hSOD1si-treated mice compared with scAAV9_hSOD1ssi (n = 15 per group). Data are presented
and ****p < 0.0001.
80 Molecular Therapy: Nucleic Acids Vol. 12 September 2018mice at end stage following injection at P40 via
cisterna magna (Figure 4G). We report a reduc-
tion in hSOD1 protein of 27% and 32% in brain-
stem (Figure 4H) and cerebellum (Figure 4I),
respectively.
A two-way ANOVA of individual gait parame-
ters over time showed a signiﬁcant improvement
in forepaw and hind paw stride length (both
p < 0.05; Figures 5A and 5C), forepaw intensity
(p < 0.05; Figure 5B), and swing speed
(p < 0.01; Figure 5D) at 91 days in SOD1G93Atransgenic mice treated with scAAV9_hSOD1si compared with
scAAV9_hSOD1ssi, indicating an improvement in motor perfor-
mance and reduced motor deﬁcits.
Design and Validation of Off-Target Effect Constructs In Vitro
Efﬁcient clinical translation of an RNAi-mediated treatment for
SOD1-linked fALS requires the development of RNAi reagents that
are free of signiﬁcant off-target effects. To test this, several shRNA
constructs in addition to the therapeutic construct (scAAV9_
hSOD1si) were generated and together screened for their ability to
silence endogenous hSOD1 mRNA by scAAV9 viral transduction
in three different cell types: (1) HEK293T cells (Figure 6A); (2) an
isogenic Tet-inducible Flp-FRT HEK293 cell line expressing either
wild-type (WT) or G93A hSOD1 transgenes (Figure 6B); and (3)
an astrocyte cell model of ALS (induced astrocytes [iAstrocytes])
derived from direct conversion of ﬁbroblasts from ALS patients and
healthy controls into induced neuronal progenitor cells,20 which are
then differentiated into astrocytes (Figure 6C). The isogenic cell
line was chosen as it was considered important to have an in vitro
model that was representative of both healthy and disease phenotypest test of AUC data showed improved rotarod performance
r group). Student’s t test showed improved mean survival
as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001,
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Figure 6. In Vitro Analysis of Off-Target Gene Regulation
(A–F) Graphs showing hSOD1 mRNA level fold change as determined by qRT-PCR in HEK293T cells transduced with 50,000 vg/cell scAAV9 viral vectors expressing off-
target constructs, harvested 120 hr post-transduction (n = 3) (A); isogenic Tet-inducible Flp-FRT HEK293 cells expressing either WT or G93A hSOD1 transduced with 50,000
vg/cell scAAV9 viral vectors expressing off-target constructs, harvested 120 hr post-transduction (n = 3) (B); iAstrocyte cells transduced with 250,000 vg/cell scAAV9 viral
vectors expressing off-target constructs, harvested 120 hr post-transduction (n = 10) (C); PCA plot of virally transduced isogenic Tet-inducible Flp-FRT HEK293 cell
microarray data colored by treatment (scAAV9_hSOD1si, blue; scAAV9_hSOD1si_2, yellow; scAAV9_misSOD1si, pink; and scAAV9_H1emp, white) (D); volcano plots
showing differentially expressed genes in scAAV9_hSOD1si transduced isogenic Tet-inducible Flp-FRT HEK293 cells (E) and iAstrocytes (F) compared to scAAV9_H1emp
transduced cells (Probeset color key: green, p < 0.05, fold change > 1.5; orange, p > 0.05, fold change > 1.5; red, p < 0.05, fold change < 1.5). SOD1 probeset is highlighted
by red dashed circles. Data are presented as the mean ± SEM. Data were analyzed by one-way ANOVA (A and C) or two-way ANOVA (B) followed by post hoc Dunnett’s
multiple comparisons test with respect to mock. *p < 0.05, **p < 0.01, and ****p < 0.0001.
www.moleculartherapy.orgbut that also avoided the inherent genetic variation of other cell
models, such as cells derived from patients. The iAstrocyte cell lines
were used due to a number of translationally relevant attributes:
(1) the availability of lines derived from healthy controls and sporadic
and SOD1-fALS patients, representing the natural genetic variation
found in the human population; (2) the relevance of including a glial
model of ALS in this study due to the increasing volume of data
pointing to a signiﬁcant role for astrocyte-mediated toxicity in the
pathobiology of ALS;21–24 and (3) the fact that astrocytes are a likely
in vivo target of the scAAV9 viral vector used in this study.
Of the additional RNAi constructs cloned into scAAV9 for the
purposes of investigating off-target effects, scAAV9_hSOD1si_2
was designed to act as a positive control for on-target gene regulation,
as it also targets hSOD1 mRNA, albeit at a different region of thegene targeted by scAAV9_hSOD1si. The shRNA sequence used in
scAAV9_hSOD1si_2 has previously shown strong therapeutic
efﬁcacy when delivered by lentivirus vector in the G93A mouse
model.8 scAAV9_misSOD1si contains the same shRNA sequence
as scAAV9_hSOD1si but differs by a central mismatch created
by changing a 3-bp central portion of the therapeutic shRNA to its
complement base pairs, resulting in a non-SOD1-targeting shRNA
that contains the same seed region sequence as scAAV9_hSOD1si.
The ﬁnal control construct consists of an H1 promoter-only
control that does not express an shRNA (scAAV9_H1emp). Both
hSOD1 mRNA-targeting shRNA constructs (therapeutic construct
scAAV9_hSOD1si and on-target control construct scAAV9_
hSOD1si_2) were found to signiﬁcantly and effectively reduce levels
of hSOD1 mRNA byR49% relative to mock, in all cell lines (Figures
6A–6C). Neither the seed control (scAAV9_misSOD1si) nor theMolecular Therapy: Nucleic Acids Vol. 12 September 2018 81
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reduce hSOD1 mRNA signiﬁcantly, relative to mock.
Gene Expression Analysis of RNAi-Mediated Knockdown of
hSOD1 In Vitro Shows No Off-Target Effects
Off-Target Effects Study in Isogenic tet-Inducible Flp-FRT
HEK293 Cells
A principal-component analysis (PCA) plot of the gene expres-
sion data, analyzed by two-way ANOVA multigroup comparison
(p < 0.05), showed clear separation of the four different treatments
into discrete groups in both inducible HEK293 cells (Figure 6D)
and iAstrocytes (Figure S1). A two-group comparison (t test) in
Qlucore Omics Explorer was used to investigate differential gene
expression between each shRNA and the negative control (scAAV9_
H1emp). Gene expression differences that displayed a p value < 0.05
were considered signiﬁcant. Filtering genes by p value (p < 0.05) and
fold change (R1.5) resulted in a list of 1 differentially expressed
gene for scAAV9_hSOD1si, 0 genes for scAAV9_misSOD1si, and 2
genes for scAAV9_hSOD1si_2. Only 1 differentially expressed gene
was shared between the knockdown constructs scAAV9_hSOD1si
and scAAV9_hSOD1si_2: SOD1, with a fold change of 2.01 and
1.53, respectively.
A volcano plot (x axis, log2 fold change; y axis, log10 p value) for
differentially expressed genes in scAAV9_hSOD1si-transduced cells
compared with scAAV9_H1emp-transduced cells shows only SOD1
passing the threshold values of p < 0.05 and fold change R1.5
(Figure 6E). Despite sharing a seed region, scAAV9_hSOD1si and
scAAV9_misSOD1si shared no common downregulated genes
compared to scAAV9_H1emp. If strong off-target effects mediated
by the shRNA seed region were present, it would be expected that
the two shRNA constructs sharing this region, scAAV9_hSOD1si
and scAAV9_misSOD1si, would cluster together and downregulate
similar genes, which was not the case. The observation that scAAV9_
misSOD1si did not downregulate any genes greater than 1.5-fold
indicates that the seed region itself does not have any afﬁnity for
any human transcript.
Off-Target Effects Study in iAstrocyte Cell Lines
To assess the off-target effect of the therapeutic vector in a more
variable and rich genetic context, gene expression data from ﬁbro-
blast-derived iAstrocyte lines transduced with scAAV9_hSOD1si,
scAAV9_misSOD1, and scAAV9_H1emp were similarly analyzed
for differential gene expression. A two-group comparison (t test) in
Qlucore Omics Explorer was used to investigate differential gene
expression between each shRNA and the negative control (scAAV9_
H1emp). scAAV9_H1emp was also compared to untransduced cells.
Filtering genes by p value (p < 0.05) and fold change (R1.5) resulted
in a list of 1 differentially expressed gene for scAAV9_hSOD1si
and 0 genes for scAAV9_misSOD1si. One gene was found to be
differentially expressed between samples transduced with scAAV9_
H1emp and untransduced samples: MIF4G Domain-Containing
protein (MIF4GD), a protein that facilitates the translation of histone
mRNA (fold change 1.66 relative to untransduced). SOD1 was the82 Molecular Therapy: Nucleic Acids Vol. 12 September 2018only differentially expressed gene seen in scAAV9_hSOD1si-trans-
duced cells (fold change,2.78 relative to scAAV9_H1emp), recapit-
ulating the results seen in the inducible HEK cell lines and further
supporting the observation that no genes other than the target
gene were downregulated in vitro by the therapeutic construct. A vol-
cano plot for differentially expressed genes in scAAV9_hSOD1si-
transduced cells compared with scAAV9_H1emp-transduced cells
shows SOD1 as the only named gene passing the threshold values
of p < 0.05 and fold changeR1.5 (Figure 6F).
DISCUSSION
In summary, this study revealed that AAV9-mediated CSF delivery of
functional shRNA molecules to the CNS causes sustained long-term
rescue of a dominantly inherited form of ALS in a transgenic mouse
model. We consider that our ﬁndings are timely and are of great rele-
vance for clinical translation for the following reasons: (1) evaluation
of the ﬁnal clinical conﬁguration of the therapeutic vector led to
remarkable efﬁcacy in a mouse model of SOD1-associated ALS;
(2) gene transfer to the CSF through the cisterna magna can be easily
translated to human clinical trials using intrathecal injection as the
route of delivery; (3) to our knowledge, this is the ﬁrst report to
demonstrate that no signiﬁcant off-target effects are linked to
AAV9-mediated SOD1 silencing using this construct, providing
further conﬁdence in the speciﬁcity and safety of the clinical thera-
peutic vector used in this study; and (4) we report the measurement
of CSF SOD1 protein levels as a biomarker, supporting future effec-
tive dosing and efﬁcacy of SOD1 knockdown in human subjects.
Previous gene therapy approaches in models of SOD1-linked ALS
have involved delivery of shRNA molecules to susceptible motor
neuron populations using retrograde transport of lentiviral vectors
following intramuscular (IM) delivery.8 Similarly, recent reports
also revealed remarkable proof of concept achieved by systemic
delivery (intravenous [i.v.]) of AAV9-mediated SOD1 silencing in
SOD1G93A transgenic mice.10,25 Advancing IM and i.v. approaches
to the clinic, however, is challenged by the high cost of manufacturing
and the large amounts of viral vector required for such modes of
vector delivery.
Cisterna magna delivery allows widespread gene transfer to the CNS
as previously reported in one of our studies.12 However, this mode of
delivery is not speciﬁc to the brain, as several reports suggest that
AAV viral particles can be detected in the periphery following CSF
administration.26 The key advantages of CSF (e.g., cisterna magna)
gene therapy administration are as follows: (1) a reduced amount of
viral vector required for this mode of delivery when compared to
systemic (i.v.) administration; and (2) the probability of reduced
amounts of viral particles reaching peripheral organs, such as the
liver, minimizing the risk of immune response and other potential
side effects.
The considerable improvement in the life expectancy of the
SOD1G93A mice observed in this report is probably a consequence
of the more direct approach used in this study for targeting expression
www.moleculartherapy.orgof the genetic factor causing the disease. Furthermore, the CSF mode
of vector delivery used in this study and the remarkable efﬁcacy
achieved illustrate the realistic potential for advancing AAV9-based
RNAi approaches to human clinical trials in SOD1 fALS. Indeed,
the AAV9 vector system has already been used in spinal muscular
atrophy (SMA), Batten disease, and giant axonal neuropathy clinical
trials,27 which provide evidence of the safety proﬁle of this vector
system and, hence, the true potential for scaling up our small inter-
fering RNA (siRNA) approach for human gene therapy trials in
SOD1-related ALS.
In contrast to previous studies, the data reported here have been
generated using a therapeutic construct that requires no further alter-
ation before entering the clinic. The construct contains no exogenous
reporter genes (e.g., GFP) and is composed of only an H1 promoter,
the therapeutic shRNA, and a sophisticated stuffer sequence designed
by the Kaspar laboratory. Despite the widespread use of GFP or
similar reporter genes in gene therapy vectors, we have found that
the removal of the GFP reporter gene and its replacement with a
stuffer sequence has had no deleterious effect on the ability of the vec-
tor construct to reduce SOD1 mRNA and protein levels in vitro or
extend survival in the mouse model in vivo. In fact, the percentage in-
crease in median survival in P1-treated animals observed in this study
(42%) compares favorably to that observed by Foust et al.,10 who used
the CBA-GFP-containing vector and observed a percentage increase
in median survival of 39% after treatment at P1. Foust et al.,10 utilized
i.v. delivery of AAV9, resulting in a considerably higher dose of
3.6  1011 vg/g compared to the dose of 5  1010 vg/g we used for
cisterna delivery. Our approach, i.e., intrathecal delivery has 2 major
advantages: (1) similar efﬁcacy is achieved compared to i.v. delivery
while administering a lower dose of therapeutic vector, therefore
yielding a potential reduction in good manufacturing practice
(GMP) manufacturing cost; (2) the amount of viral particles reaching
peripheral organs, such as the liver, is likely to be reduced when
compared to i.v. delivery, therefore reducing the risk of side effects.
Consistent with previous studies in mice and non-human primates,26
intrathecal delivery allows reducing the viral dose by 10 times and
achieving comparable results.
The lack of paralysis and continued ability of scAAV9_hSOD1si-
treated animals to remain ambulant even at end stage is consistent
with our observation of increased motor neuron count. Expression
of mutant SOD1 in non-neuronal cells, such as glia, has also been
demonstrated to have an inﬂuence on the progression of motor
neuron degeneration in in vivo28–31 and in vitro21,32 ALS models.
Since the CSF mode of delivery of AAV9 described here targets
both motor neuron and glial populations, the prevention of the dele-
terious effects of mutant SOD1 expression in non-neuronal cell types
may also have contributed to the delayed onset of disease symptoms
in these animals. Consistent with this, we observed reduced gliosis in
the spinal cord of therapeutically treated mice compared to controls.
The reason behind the lack of a complete rescue is unclear. A group of
AAV9_hSOD1si-treated SOD1 mice showed ALS-like symptomswith modest extension in survival and was humanely euthanized.
A proportion of mice did not die as a consequence of motor impair-
ment, since the motor function and behavior of these animals
remained signiﬁcantly higher compared to untreated and scramble
vector-treated mice. In particular, this second group of mice suddenly
looked moribund and died overnight or were humanely culled. A
gene therapy study of virally mediated hSOD1 mRNA reduction
by artiﬁcial microRNA in the same mouse model reported a similar
preservation of limb function in treated mice, with euthanasia initi-
ated due to severe weight loss and excessive curvature of the spine
(kyphosis), which the authors postulate was a symptom of weakening
of the intercostal muscles and diaphragm.33 As respiratory failure is
the most common cause of death in ALS patients, this may point to
a similar involvement of diaphragm weakness in the death of the
treated mice in our study and of those in Stoica et al.,33 with potential
future implications for targeting of this structure by therapies.
Complete rescue of the model is also likely hindered by the extremely
high burden of mutant SOD1 protein in the SOD1-G93A line—many
times that of a human patient—resulting from the multiple transgene
copies present in the line. Insufﬁcient transduction of CNS neurons/
glia or even other peripheral organs could be behind early death or
the lack of a complete rescue. Indeed we observed variability in viral
particle biodistribution, suggesting technical variability during
cisterna magna administration of the AAV9 virus.
Our efforts went beyond establishing in vivo proof-of-concept efﬁcacy
of the therapeutic strategy. Indeed, to our knowledge this is the ﬁrst
report to demonstrate that AAV9-mediated SOD1 silencing can be
achieved without signiﬁcant off-target effects, providing further con-
ﬁdence in the speciﬁcity and safety of the clinical therapeutic vector
developed by the Kaspar group. Although exogenous shRNA mole-
cules are designed to be fully complementary to their target transcript,
and efforts are made in silico to search for sequences that do not have
any complementarity with other genes, off-target effects can occur
whereby shRNAmolecules act like endogenous microRNA (miRNA)
molecules. miRNA molecules in vivo often bind to the 30 UTRs of
multiple mRNA transcripts, exhibiting only partial sequence comple-
mentarity and regulating gene expression by translational inhibi-
tion.34,35 Acting in this way, even an siRNA or shRNA designed to
be highly speciﬁc to a target transcript may downregulate the expres-
sion of multiple gene products.36–38
Off-target miRNA-like silencing in shRNA molecules is mediated
by nucleotides 2–8 in the anti-sense strand of an shRNA molecule,
analogous to the 7-nt seed region that mediates gene repression in
endogenous miRNAs.39,40 In light of this, several control constructs
were cloned into the scAAV9 plasmid backbone to allow detection
of seed region-mediated off-target effects (Table S1). Previous studies
into off-target effectsmediated by siRNAs have shownwidespread off-
target gene regulation.37,39,41,42 However, others have shown reduced
off-target effects when using virally delivered shRNA constructs
compared with transfected siRNA constructs, albeit using lentivirus
rather than AAV.43,44 Reports investigating shRNA-mediatedMolecular Therapy: Nucleic Acids Vol. 12 September 2018 83
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genes in addition to the target gene, in accordance with the observa-
tions in this study.44,45
The lack of observable off-target effects in vitro using our therapeutic
vector is very encouraging, and it will hopefully be supported by the
regulatory safety studies required for advancing this strategy to hu-
man clinical trials. Furthermore, we report the measurement of CSF
SOD1 protein levels as a biomarker of effective dosing and efﬁcacy
of SOD1 knockdown. This approach is likely to prove useful in hu-
man clinical trials to assess the biological activity of the therapeutic
vector. Together, our data highlight the considerable therapeutic
potential of RNAi for treating a dominantly inherited neurological
disease, and they provide optimism for the future translation of
AAV9-RNAi from a research tool to a therapeutic agent.
MATERIALS AND METHODS
Ethics Statement
All animal in vivo experiments were approved by the University of
Shefﬁeld Ethical Review Sub-Committee, the UK Animal Procedures
Committee (London, UK), and they were performed according to the
Animal (Scientiﬁc Procedures) Act 1986, under the Project License
40/3739. SOD1G93A mice were maintained in a controlled facility in
a 12-hr dark/12-hr light photocycle (on at 7 a.m./off at 7 p.m.) with
free access to food and water. The Animal Research: Reporting of
In Vivo Experiments (ARRIVE) guidelines have been followed in
reporting this study.46 We employed a double-blind randomization
process in which experimental groups were blinded to the individuals
conducting viral delivery and data analyses (e.g., motor neuron
counts).
AAV Construction and Preparation
The original pAV2 vector backbone was published in Foust et al.10
Brieﬂy, within the vector inverted terminal repeats (ITRs), an H1 pro-
moter drives expression of the shRNA targeted against the hSOD1
gene. A stuffer sequence has been added to optimize the packaging
efﬁciency of the vector backbone kindly provided by Brian Kaspar.
This plasmid has an 11-bp deletion in the downstream ITR, removing
a target site that would otherwise be cleaved by the AAV endonu-
clease during capsid assembly and packaging. The consequence of
this deletion is the formation of palindromic repeats of the viral
genome, able to fold into a double-stranded DNA (dsDNA) hairpin
structure referred to as a self-complementary genome. A separate vec-
tor used as a scrambled shRNA virus control (scAAV9_hSOD1ssi)
contained a non-targeting shRNA under the control of the H1
promoter, as well as a cytomegalovirus (CMV)-GFP reporter gene
construct.
Cisterna Magna Delivery of scAAV9_hSOD1si or
scAAV9_hSOD1ssi in SOD1G93A Mice
scAAV9-mediated gene delivery was applied via the cisterna magna
at two different time points: pre-onset (P1) and onset (P40) of symp-
toms. We chose onset as P40 as functional and structural changes in
motor units are reported as starting from this time point in SOD1G93A84 Molecular Therapy: Nucleic Acids Vol. 12 September 2018mice.47,48 In an initial study, 30 SOD1G93A transgenic mice were
divided into two groups to be treated at P40 with either scAAV9_
hSOD1si or scrambled control virus scAAV9_hSOD1ssi (12 mL total
injection volume, 2 mL iodixanol and 10 mL virus; virus concentration,
1.2  1013 vg/mL; total dose, 5  1010 vg/g). In a second study,
19 SOD1G93A transgenic mice were divided into 2 groups to be treated
at P1 with either scAAV9_hSOD1si (n = 9) or scrambled control virus
scAAV9_hSOD1ssi (n = 10) (total dose, 8  109 vg/g). A cohort of
10 mice per group (scAAV9_hSOD1si and scAAV9_hSOD1ssi) was
injected at P1 and sacriﬁced 4 weeks post-injection to assess viral
biodistribution and hSOD1 mRNA and protein levels (in striatum,
brainstem, cerebellum, cortex, lumbar spinal cord, and CSF). The
remaining mice underwent behavioral testing to assess effects on
disease progression, achieved by the use of weekly rotarod analysis
after 3 consecutive days of training.
In all studies, the onset and progression of disease were estimated by
neurological scoring three times per week from 60 days of age. Body
weight was recorded weekly. Mice were scored for tremor, hind limb
splay, and overall neurological deﬁcit using a previously reported
scoring system.49 Disease onset was deﬁned as the point at which
both enhanced tremor and defective hind limb splay were ﬁrst
observed. All mice continued to end-stage disease and the time to
reach this stage was recorded. The humane endpoint is deﬁned as
the inability to right within 10 s of being placed onto the back or
weight loss of more than 30% over 72 hr. Mice were distress scored
daily from 120 days onward. All animals were perfused under
terminal anesthesia, and CNS tissue was collected to assess viral bio-
distribution and SOD1 mRNA and protein levels. Injected animals
displaying low levels of viral biodistribution, as measured by qPCR,
were excluded from subsequent analysis.
Genotyping and Copy Number Analysis
Genotyping and copy number analysis of SOD1G93A mice was per-
formed based on the protocol described in Mead et al.49 Any changes
made are detailed below.
Mouse genotyping was performed on genomic DNA extracted from
tail tissue using the Maxwell 16 system DNA puriﬁcation kit (Prom-
ega, WI, USA). Genotyping PCRs were performed on genomic DNA
in a 25-mL volume with ABgene ReddyMix (ABgene, Epsom, UK),
150 nM each of hSOD1 primers (forward, 59-CATCAGCCCTAAT
CCATCTGA-39; reverse, 50-CGCGACTAACAATCAAAGTGA-30)
and control interleukin-2 receptor (IL-2R) primers (forward, 50-CTA
GGCCACAGAATTGAAAGATCT-30; reverse, 50-GTAGGTGGAA
ATTCTAGCATCATC-30). Following PCR and agarose gel electro-
phoresis (3% agarose gel), IL-2R PCR products were visualized at
324 bp and hSOD1, if present, at 236 bp. Mice positive for transgene
expression were then subjected to copy number analysis by qPCR
using 30 ng cDNA, 2 SYBR Green PCR Master Mix (Agilent Tech-
nologies, CA, USA), and 150 nM primers used for genotyping, in a
total volume of 20 mL. Following an initial denaturation at 95C
for 10 min, DNA was ampliﬁed by 40 cycles of 95C for 15 s and
60C for 1 min, on anMX3000P Real-Time PCR System (Stratagene).
www.moleculartherapy.orghSOD1/IL-2R DCt values from samples were compared to a reference
DNA sample from an SOD1G93A control mouse displaying a pheno-
type consistent with one carrying the full 25 copies of the transgene.
CSF Collection and ELISA for hSOD1 Quantification
SOD1G93A mice were placed on a stereotaxic frame under general
anesthesia by isoﬂurane inhalation. The head was secured with ear
adaptors and the skin of the neck was shaved. A sagittal incision of
the skin was made inferior to the occiput. The subcutaneous tissue
and muscles (m. biventer cervicis andm. rectus capitis dorsalis major)
were separated by blunt dissection with forceps. A pair ofmicroretrac-
tors was used to hold the muscles apart. A capillary tube was inserted
into the cisterna magna through the dura mater as previously
described.50 Following a change in resistance to the capillary tube
insertion, the CSF ﬂowed into the tube and was transferred into a
0.5-mL Eppendorf tube containing 20 mL 0.1 M PBS. The CSF sample
was spun for 4 min to pellet any contaminating cells, transferred to
a fresh tube, snap frozen in liquid nitrogen, and stored at 80C.
hSOD1 was measured in CSF from SOD1G93A mice using the Human
Cu/ZnSOD Platinum ELISA kit (BMS222, eBioscience, San Diego,
CA, USA), according to the manufacturer’s instructions. Brieﬂy,
1–4mL blood-free CSF samples were collected and added to 20mL ster-
ile 0.1M PBS and stored at80C. All samples were quantiﬁed for to-
tal protein concentration using a Bradford assay to normalize loading
to total protein. The quantiﬁcation for hSOD1 protein was performed
in duplicate using 0.2 mg total protein per assay well, and the resulting
average value was expressed as ng hSOD1/mg CSF total protein.
qRT-PCR for hSOD1 mRNA Knockdown Analysis
qRT-PCR was carried out using 2 mL total RNA diluted to a con-
centration of 10 ng/mL in nuclease-free water, 5 mL 2 QuantiFast
SYBR Green RT-PCR Master Mix (QIAGEN), hSOD1 (forward,
50-TCACTTTAATCCTCTATCCAGAAAACAC-30; reverse, 50-ACC
ATCTTTGTCAGCAGTCACATT-30; 1 mM) and 18S (forward, 50-GT
AACCCGTTGAACCCCAT-30; reverse, 50-CCATCCAATCGGTAG
TAGCG-30; 1 mM) primers, 0.1 mL QuantiFast RT mix, and H2O to a
ﬁnal volume of 10 mL. Following an RT step at 50C for 10 min and
5 min at 95C, cDNA was ampliﬁed by 39 cycles of 95C for 10 s
and a combined annealing and extension step at 60C for 10 s. This
was followed by one cycle at 65C for 31 s, before analysis bymelt curve
step. All qRT-PCRwas performed on a Bio-RadC1000TouchThermal
Cycler. Bio-Rad CFX Manager software was used to analyze signal
intensity, and relative gene expression values were determined using
the DDCt method, with 18S rRNA used as a reference gene.
Rotarod
Ugo Basile 7650 accelerating rotarod (set to accelerate from 3 to
37 rpm over 300 s) was used to measure motor function from day
35 onward. Rotarod training was performed over 3 consecutive
days, with two trials per day. Subsequently, this test was performed
at weekly intervals in the late morning. For each evaluation, the
mice were tested twice, with a rest period between runs. The best per-
formance, measured as latency to fall in seconds, was used for anal-
ysis. The minimum threshold for recording rotarod activity was 3 s.Gait Analysis
The catwalk gait analysis system version 7.1 was used to assess gait
parameters in ﬁve SOD1G93A mice per group. Mice were tested at 9,
11, and 13 weeks of age. They were placed on the catwalk apparatus
in complete darkness, and the recording of gait patterns was per-
formed in a separate room. Six runs were recorded for each mouse
and two selected for analysis. The runs to be analyzed were selected
based on the absence of behavioral anomalies, such as snifﬁng, explo-
ration, and rearing, and where mouse locomotion was steady without
noticeable accelerations or decelerations. Processing of gait data was
performed with the Noldus software. Limbs were assigned manually
and gait parameters were calculated automatically.
Protein Extraction and Western Blotting for hSOD1 Protein
Knockdown Analysis
Spinal cords and dissected brain regions were harvested from end-
stage P40 SOD1G93A mice treated with scAAV9_hSOD1si or scram-
bled control scAAV9_hSOD1ssi and snap frozen in liquid nitrogen.
Tissue was homogenized using a dounce homogenizer in ice-cold
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCL
[pH 7.4], 1% v/v NP-40, 0.5% w/v sodium deoxycholate, 0.1% v/v
SDS, 150mMNaCl, and 2mMEDTA) containing 1 protease inhib-
itor cocktail (Sigma-Aldrich). Lysate protein concentrations were
determined using the bicinchoninic assay (BCA; Thermo Scientiﬁc
Pierce); 10 mg protein lysate was denatured by heating to 100C for
5 min in the presence of 4 loading buffer (10 mL buffer contained
240 mM Tris-HCL [pH 6.8], 8% w/v SDS, 40% glycerol, 0.01% bro-
mophenol blue, and 10% b-mercaptoethanol). Lysates were then
loaded onto 4%–20% gradient mini-PROTEAN TGX precast poly-
acrylamide gels (Bio-Rad). Gels were run at 160 V in running buffer
(25 mM Tris, 192 mM glycine, and 0.1% SDS [pH 8.3]) until the dye
front reached the bottom of the gel (45 min).
Separated proteins were transferred by semi-dry electrophoresis to
a polyvinylidene ﬂuoride (PVDF) membrane using the Invitrogen
iBlot2 transfer system, as per standard manufacturer’s protocol.
Membranes were blocked for 1 hr in 5% “milk/TBS-T”. Primary
antibodies mouse anti-a-tubulin (1:5,000) and rabbit anti-hSOD1
(1:1,000) were diluted in 5% “milk/TBS-T” and incubated with the
membrane overnight at 4C. After primary antibody incubation,
the membrane was washed for 3  15 min each in TBS-T buffer.
Secondary antibodies anti-mouse horseradish peroxidase (HRP)
(1:3,000) and anti-rabbit HRP (1:3,000) were diluted in 5% “milk/
TBS-T” and incubated with the membrane for 2 hr at room tem-
perature. After secondary antibody incubation, the membrane was
washed for 3  15 min each in TBS-T buffer. Protein bands were
visualized using EZ-ECL reagent (Geneﬂow) and the G-Box imaging
system (Syngene). Densitometric analysis of protein bands was
carried out using ImageJ software.
Immunofluorescence
All mice were deeply anaesthetized with pentobarbital and perfused
transcardially with 100 mL room temperature 0.1 M PBS followed
by 100 mL ice-cold 4% paraformaldehyde (PFA). Lumbar spinalMolecular Therapy: Nucleic Acids Vol. 12 September 2018 85
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by 30% sucrose in 0.1 M PBS until sunk. Immunohistochemistry
was performed according to Lukashchuk and colleagues.12 In brief,
the tissues were embedded in optimal cutting temperature (OCT),
and 25-mm-thick spinal cord sections were cut on a cryostat (Leica
CM3050S) at 22C free ﬂoating. Spinal cord sections were washed
twice with PBS, permeablized in PBS/0.3% Triton X-100, blocked
with 10% normal goat serum (NGS) in PBS/0.3% Triton X-100 solu-
tion for up to 3 hr, and incubated with primary antibody anti-CGRP
(1:500; Abcam), GFAP (1:1,000, Sigma), or Iba1 (1:1,000, Abcam)
diluted in 2% NGS in 0.1 M PBS/0.15% Triton X-100 overnight.
The following day, sections were washed in 0.1 M PBS four times
for up to 2 hr and incubated with secondary antibodies Alexa Fluor
anti-mouse 568 or Alexa Fluor anti-mouse 488 (Life Technologies,
CA, USA) diluted in 5%NGS/PBS for 1 hr. For visualization of nuclei,
1:2,500 Hoechst stain (Sigma, MI, USA) diluted in 0.1 M PBS was
used. Images were captured using a Leica confocal microscope and
were processed using LAS AF Lite software and ImageJ.
Nissl Staining and Quantification of Motor Neurons
Lumbar spinal cord was ﬁxed overnight in 4% PFA and cryoprotected
in 30% sucrose in 0.1 M PBS. OCT-embedded lumbar cord was cut by
cryostat (Leica CM3050S) into 20-mm-thick sections andmounted on
charged glass slides. Sections were ﬁxed in cold acetone for 10 min,
then stained with 1% w/v aqueous cresyl violet acetate solution for
2 min. Sections were rinsed with water before being destained with
0.25% acetic acid in ethanol. Sections were dehydrated by passing
through an ethanol gradient and cleared by brief immersion in xylene
before coverslipping. Slides were visualized using a Hamamatsu
NanoZoomer and NDP.view2 viewing software. Motor neurons
within the ventral horn of the lumbar cord were identiﬁed by their
morphology and size. Motor neurons in every ﬁfth section were
counted, one ventral horn region per section, with a total of 10 sec-
tions per mouse counted (n = 3 mice per treatment group).
Cell Culture
HEK293T cells were cultured at 37C and 5% CO2 in growth media
consisting of DMEM (Sigma) supplemented with 10% v/v fetal bovine
serum (FBS, Sigma, MI, US) and 1% v/v penicillin/streptomycin
(Lonza, Basel, Switzerland).
Isogenic Tet-inducible Flp-FRT HEK293 cells were created using the
Flp-In T-REx system (Invitrogen). Cells were cultured in the same
conditions as HEK293T cells detailed above, with the addition of
15 mg/mL blasticidin and 100 mg/mL hygromycin and the use of tetra-
cycline-free FBS (Biosera). Isogenic Flp-FRT cells contained either a
WT or G93A transgene under the control of a tetracycline-inducible
CMV promoter, allowing regulated overexpression of the transgene.
Expression of the recombinant gene of interest was induced by the
addition to the culture media of 1 mg/mL tetracycline during seeding
of the cells into cell culture plates.
The iAstrocytes derived from human ﬁbroblasts were generated by
the process detailed in Meyer et al.20 Brieﬂy, ﬁbroblasts were trans-86 Molecular Therapy: Nucleic Acids Vol. 12 September 2018duced with retroviral vectors expressing four reprogramming
factors (Sox2, KLF4, Oct3/4, and c-Myc). After transduction, cells
were cultured in growth media containing FGF2, EGF, and heparin
to promote the conversion of ﬁbroblasts to induced neuronal progen-
itor cells (iNPCs). iNPCs were further differentiated to iAstrocytes by
plating onto a ﬁbronectin-coated culture dish and changing the
growth media to DMEM (Sigma) supplemented with 10% FBS
(Sigma), 1% v/v penicillin/streptomycin (Lonza), and 0.3% N2 (Life
Technologies). iAstrocytes used in transduction studies were cultured
at 37C and 5% CO2 in the growth media used for differentiation.
Plasmid and Viral Construct Production for Off-Target Effects
Analysis
Off-target analysis constructs (scAAV9_hSOD1si_2, scAAV9_
misSOD1si, and scAAV9_H1emp) were cloned into the scAAV9_
hSOD1si plasmid backbone using the oligonucleotide sequences
listed in Table S1. scAAV9 viral vectors containing the off-target con-
structs were produced by the Children’s Hospital of Philadelphia
(CHOP) and the viral titer was determined by qPCR.
Validation of Off-Target Constructs In Vitro
HEK293T and isogenic Tet-inducible Flp-FRT HEK293 cells were
transduced 24 hr after plating with 50,000 vg/cell mixed with normal
growthmedia. iAstrocyte cell lines were transduced 24 hr after plating
with 250,000 vg/cell mixed with normal growth media. All cell lines
were incubated with virus for 5 days before being harvested for anal-
ysis of hSOD1 knockdown by western blot and qRT-PCR.
Microarray Analysis of Off-Target Effects
Total RNA, extracted from Tet-inducible Flp-FRT HEK293 and
iAstrocyte cells transduced with scAAV9 vectors expressing the off-
target constructs (HEK293 cells, 50,000 vg/cell, collected 5 days
post-transduction; iAstrocyte cells, 250,000 vg/cell, collected 5 days
post-transduction), was analyzed by whole-genome microarray
(HEK293 cells, 30 IVT Express kit using GeneChip Human Genome
U133 Plus 2.0 Arrays [Thermo Fisher Scientiﬁc]; iAstrocytes, Gene-
Chip WT Plus reagent kit using Clariom S Human whole transcript
arrays [Thermo Fisher Scientiﬁc]) to investigate gene expression
changes elicited by treatment with the viral vectors. RNA quality
was measured as the RNA integrity number (RIN) using the Bio-
analyzer 2100 system (Agilent Technologies, CA, USA) and RNA
6000 Nano LabChip kit (Agilent Technologies, CA, USA). Array
data CEL ﬁles were normalized and quality control checked in
Affymetrix Expression Console software. Differential gene expression
between treated and control arrays was determined using Robust
Multi-array (RMA)-normalized data analyzed in Qlucore Omics
Explorer (Qlucore AB, Lund, Sweden).
Statistical Analyses
Data were analyzed using GraphPad Prism 6 software (GraphPad,
San Diego, CA, USA). Behavioral studies were statistically analyzed
using a two-way ANOVA with repeated measures followed by Sidak’s
post hoc test (for rotarod and neuroscoring) and unpaired Student’s
t test for AUC data of rotarod, neuroscoring, and survival. For in vivo
www.moleculartherapy.orgknockdown of hSOD1 mRNA and protein determined by qRT-PCR
and western blot analysis, respectively, comparisons were achieved
by unpaired one-tailed Student’s t test. For immunohistochemical
studies, data were analyzed using unpaired Student’s t test. For
in vitro analysis of knockdown by off-target constructs in HEK293
cells and iAstrocyte cell lines, one-way ANOVA followed by Dun-
nett’s post hoc test was used. For in vitro analysis of knockdown
by off-target constructs in isogenic Tet-inducible Flp-FRT HEK293
cell lines, two-way ANOVA followed by Dunnett’s post hoc test
was used. Differential gene expression analysis from microarray
data for each shRNA construct was determined by Student’s t test
between that construct and the scAAV9_H1emp promoter-only
control construct.
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